Tag Archives: amiodarone

X-VERT: rivaroxaban▼ an alternative to VKA in cardioversion for AF Watch Professor Keith Fox, Chairman of the ESC programme committee discussing the relevance of X-VERT and other studies for UK practice in our podcast from the ESC Oral anticoagulant therapy with rivaroxaban is an alternative to vitamin K antagonists (VKAs) in patients with AF who are undergoing elective cardioversion according to the results of the X-VERT study.1 In addition, rivaroxaban may potentially have one important advantage over VKAs, with a shorter time to cardioversion, the study suggests. Professor Riccardo Cappato (University of Milan, Italy), the co-principal

Amiodarone for the treatment of stable ventricular tachycardia – has the Resuscitation Council got it wrong? Dear Sirs, Amiodarone has been the UK Resuscitation Council’s recommendation for the treatment of haemodynamically stable ventricular tachycardia (VT) since 2000.1  It is my opinion that the evidence in support of amiodarone in this setting is poor and that superior agents may exist. In the last six years, three retrospective studies have been published showing a dismal success rate when amiodarone is used to treat patients with stable VT. Marill et al reported that eight out of 28 (29%) patients cardioverted using a dose of 150 m

Introduction Statins are increasingly used for primary and secondary prevention of cardiovascular disease, and in the UK simvastatin is now available as an ‘over-the-counter’ drug without prescription. Rhabdomyolysis is a rare and potentially life-threatening complication of statin therapy and with the wider use of statins there is an increased probability of drug interactions, which may increase the incidence of myopathy and rhabdomyolysis. Early recognition is essential to prevent serious consequences. We report a case of rhabdomyolysis complicated by acute renal failure associated with the concomitant use of high-dose simvastatin and a

No content available

No content available